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In tro duc ti on
Subcutaneous fat necrosis of the newborn (ScFN) is a rare
condition and its pathophysiology is unknown. It is usually
reported in term newborns, but may occur in preterms as well
(1,2,3,4). The skin lesions of ScFN can be described as firm
and painful subcutaneous nodules, the appearance of which
may vary from an erythematous to a violaceous lesion. Typical
lesions are mainly localized on the back, buttocks, shoulders,
and the cheeks. In general, they are self-limiting and resolve
spontaneously within a few weeks to months after the onset
(1,2,3). Hypercalcemia, occurring after healing of skin lesions,
is the most dangerous complication of ScFN. It can be 
life-threatening if not treated adequately (1,2,3).
We present the case of a newborn with uncomplicated
hypercalcemia resulting from ScFN and its management 
during the 4 months of follow-up.
Case Report 
A 3-day-old female newborn was transferred to our 
hospital due to suspected neonatal sepsis and presence of a
small omphalocele. She was born at term by spontaneous
vaginal delivery. We learned that she had undergone transient
tachypnea as well as upper gastrointestinal bleeding and
hypotension after birth. On admission, physical examination
revealed mild tachypnea, an omphalocele, and multiple 
erythematous skin lesions. Her skin lesions were located on
ABS TRACT
Subcutaneous fat necrosis of the newborn (ScFN) is an uncommon 
condition caused by generalized and/or local tissue hypoperfusion. The
skin lesions of ScFN tend to improve spontaneously. However, ScFN may
also lead to complications which cause serious problems. The severity
of the etiologic factors contributing to the development of the disease
determines the severity of complications. Therefore, these patients
should be closely monitored for complications, especially for 
hypercalcemia which may be life-threatening. The severity and duration
of hypercalcemia are associated with the extensity of skin lesions. 
We present a newborn who developed ScFN as a result of systemic
hypotension. The ScFN resolved after the first few weeks of life, but the
patient developed mild hypercalcemia during the 4-month follow-up
period. The infant was breast-fed during follow-up, and vitamin D 
prophylaxis was not initiated. The hypercalcemia resolved within four
months without any complications. We would like to draw attention to
the need to monitor serum calcium levels in these infants and to refrain
from initiating vitamin D prophylaxis in the first months of life.  
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the back, shoulders, the lateral surfaces of the arms, and on
the anterior medial side of the right thigh. Laboratory 
investigations, including complete blood count, serum 
calcium (Ca), phosphorus (P), alkaline phosphatase (ALP),
blood urea nitrogen, creatinine, electrolytes, blood sugar,
aspartate transaminase, alanine transaminase, acid-base 
values, and C-reactive protein levels as well as urinalysis were
all normal. Antibiotic therapy was initiated because infection
could not be ruled out and terminated after three days  when
blood cultures were reported to be sterile. The patient’s
tachypnea resolved on oxygen therapy within 24 hours and
the omphalocele was corrected surgically on the fifth day of
admission. On the first week of admission, the skin lesions
transformed into red-purple, firm and painful subcutaneous
nodules (Figure 1).  These findings were consistent with 
the early lesions of fat necrosis of the newborn, and a skin
biopsy was performed. Pathological examination of the 
biopsy material obtained from the lesion border revealed a
small number of lymphocytes and focal inflammatory areas
consisting of histiocytes (Figure 2a). Additionally, there were
radial eosinophilic crystals in the fat cells (Figure 2b). Based
on these findings, the patient was diagnosed as ScFN.
Spontaneous improvement was observed in the lesions 
during the first  two weeks following the diagnosis. The baby’s
parents were informed about the risk of hypercalcemia and its
signs and symptoms. The patient was discharged on the 15th
day of admission. Vitamin-D prophylaxis was not initiated. The
lesions progressively disappeared over the following four
weeks without any complication.  Serum Ca and P levels were
monitored twice per month after discharge. Serum Ca, P,
ALP, and parathyroid hormone (PTH) levels during admission
and follow-up were all within normal ranges and are given in
Table 1. A slight increase was noted in  serum Ca levels 
during the follow-up period. The patient was breast-fed
throughout the follow-up period. 
Discussion
ScFN is a rare condition which can be self-limiting in 
its early period, but which can be life-threatening in its late
period. Usually, the history of ScFN patients  reveals a 
systemic and/or local hypoxia-hypoperfusion episode during
the perinatal period. Possible risk factors for ScFN are 
perinatal asphyxia, meconium aspiration, cord accidents,
hypothermia-cold exposure, hypoglycemia and lactic acidosis
(1,2,3). ScFN may also develop as a complication of 
therapeutic hypothermia applied either in newborns with 
perinatal asphyxia or in newborns undergoing surgical 
procedures (5,6,7). Maternal conditions which lead to 
disrupted placental perfusion such as pre-eclampsia, 
smoking, cocaine exposure, and diabetes may also 
cause ScFN (1,2,3,7). Our patient had no history of perinatal
asphyxia or obstetric trauma and there were no maternal risk
factors. However, she had undergone a systemic hypotension
episode in the first days of life. 
In ScFN patients, typical skin lesions appear any time after
birth up to four weeks after delivery and begin with edema in
the affected skin area.  The swelling is followed by hard 
nodules and plaques (1,2,3). The lesions are very painful (2,8)
and, as was also the case in our patient, they resolve 
spontaneously within a few weeks. In some cases, as the skin
lesions heal, they lead to fat tissue atrophy, fibrosis, scarring
or ulcers (1,2,3). At admission, our patient had erythematous
lesions that transformed into red-purple, firm and painful 
subcutaneous nodules at the end of the first week (Figure 1). 
Deep hemangioma, lipoedema (cellulite), erysipelas, 
histiocytosis, fibromatosis, rhabdomyosarcomas and 
neonatal sclerema must be considered in the differential 
diagnosis of ScFN. Neonatal sclerema may occur concomitantly
with ScFN (1,2,3,7). Definitive diagnosis of ScFN requires
histopathological assessment, which will reveal 
radially arranged fat cells seen as needle-shaped crystals,
Fi gu re  1. Erythematous skin lesions, red-purple in color were located on
the back, shoulders, the external surfaces of the arms, and on the 
anterior medial side of the thighs
Fi gu re  2.  Focal nonspecific inflammation consisting of histiocytes and
lymphocytes (a), eosinophilic crystals with radial extension in the 
necrotic fat cells (b)
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multinucleated giant cells forming the granulomatous 
structure, fibroblasts, numerous histiocytes, and small
amounts of lymphocyte infiltration (1,2,3,7,9). In our patient,
also the diagnosis of ScFN was confirmed by skin biopsy. 
The size and severity of the lesions as well as the 
complications depend on the etiologic factors. Conditions
accompanied by generalized hypoxia-hypoperfusion cause the
most serious problems (1,2,3). Other than local skin problems,
thrombocytopenia, hypoglycemia, hypertriglyceridemia and
hypercalcemia constitute the expected complications of
ScFN. All complications, except hypercalcemia, are self-
limiting disorders and rapidly respond to treatment. There
were no complications except for mild elevation of blood 
calcium level in our patient. 
Hypercalcemia is the most frequently reported and 
frightening complication  in ScFN, occurring in 28-69% of the
cases (1,2,3). The pathogenesis of the hypercalcemia is 
attributed to the necrosis that occurs in the damaged 
immature fat tissue caused by granulomatous cell infiltration.
These macrophages in the area of infiltration lead to increased
1,25-dihydroxyvitamin D3 [1,25(OH)2D3] production, which,
regardless of PTH level, leads to increased intestinal 
absorption of calcium (1,2,3,7).  Release of calcium from 
necrotic fat cells, increased osteoclastic activity due to 
elevated PTH and effect of local prostaglandins (PgE2) have
been reported as other suspected mechanisms leading 
to hypercalcemia (1,2,3). The severity and duration of 
hypercalcemia are related to the severity and duration of skin
lesions. Hypercalcemia usually develops in the 4th to 6th weeks
of life, when the skin lesions begin to resolve and may last up to
the 6th month. If the duration of hypercalcemia is prolonged,
metastatic calcifications, nephrocalcinosis and renal failure may
develop and may lead to life-threatening cardiac problems
(1,2,3,7,9). The close monitoring of serum calcium levels is 
imperative in ScFN patients and their parents should be informed
about the symptoms of hypercalcemia, such as irritability,
anorexia, constipation, and failure to thrive (7,8). 
In conclusion, patients with ScFN should be followed
closely in the first months of life, since the complications 
can be life-threatening. Also, these infants should not receive
vitamin D for rickets prophylaxis in the first 6 months.
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Tab le  1. Serum Ca, P , ALP and PTH levels during the follow-up period
Ca P ALP PTH Treatment
(8.5-10.5 mg/dL) (4-7mg/dL) (75-315 U/L) (11.1-79.5 pg/mL)
15th day 9.6 mg/dL 5.2 mg/dL 106 U/L - PO Vit-D3 not initiated 
45th day  10.8 mg/dL 6 mg/dL 205 U/L - none
2nd month 10.5 mg/dL 5 mg/dL 314 U/L 30.56 pg/mL none
3rd month 10.7 mg/dL 5 mg/dL - - none
4th month 10.2 mg/dL 6 mg/dL 231 U/L - none
Ca: calcium, P: phosphorus, ALP: alkaline phosphatase, PTH: parathyroid hormone
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